B Boylan1, C H Miller1. 1. Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract
INTRODUCTION: The use of pre-analytical heat treatment (PHT) with the Nijmegen-Bethesda assay (NBA) for inhibitors to factor VIII (FVIII) can remove/destroy infused or endogenous FVIII from patient plasma samples, allowing testing of recently infused patients with haemophilia. Two PHT methods have been described as follows: heating to 56°C for 30 minutes and heating to 58°C for 90 minutes. Data examining the effects of PHT on anti-FVIII IgG4 , the antibodies known to correlate most closely with the presence of FVIII inhibitors, are limited. AIM: To assess the effect of PHT on the levels of detectable anti-FVIII IgG4 . METHODS: Nijmegen-Bethesda assay-positive specimens were incubated at 56, 58 or 60°C for 90 minutes, and anti-FVIII IgG4 was measured by fluorescence immunoassay (FLI) at 30-minute intervals. The effects of PHT on the ability of recombinant FVIII (rFVIII) to inhibit detection of patient antibodies by FLI was also examined to assess the stability of rFVIII under the various PHT conditions tested. RESULTS: Levels of anti-FVIII IgG4 showed little change following incubations at 56°C (mean 101% of original value at 30 minutes and 100% at 60 minutes) but decreased upon exposure to 58°C (mean 85% at 30 minutes and 66% at 60 minutes). In addition, heating to 56°C effectively decreased the ability of rFVIII to block antibody binding compared to unheated rFVIII. CONCLUSION: The optimal temperature for PHT in the FVIII NBA is 56°C. Higher temperatures may lead to loss of inhibitory antibodies.
INTRODUCTION: The use of pre-analytical heat treatment (PHT) with the Nijmegen-Bethesda assay (NBA) for inhibitors to factor VIII (FVIII) can remove/destroy infused or endogenous FVIII from patient plasma samples, allowing testing of recently infused patients with haemophilia. Two PHT methods have been described as follows: heating to 56°C for 30 minutes and heating to 58°C for 90 minutes. Data examining the effects of PHT on anti-FVIII IgG4 , the antibodies known to correlate most closely with the presence of FVIII inhibitors, are limited. AIM: To assess the effect of PHT on the levels of detectable anti-FVIII IgG4 . METHODS: Nijmegen-Bethesda assay-positive specimens were incubated at 56, 58 or 60°C for 90 minutes, and anti-FVIII IgG4 was measured by fluorescence immunoassay (FLI) at 30-minute intervals. The effects of PHT on the ability of recombinant FVIII (rFVIII) to inhibit detection of patient antibodies by FLI was also examined to assess the stability of rFVIII under the various PHT conditions tested. RESULTS: Levels of anti-FVIII IgG4 showed little change following incubations at 56°C (mean 101% of original value at 30 minutes and 100% at 60 minutes) but decreased upon exposure to 58°C (mean 85% at 30 minutes and 66% at 60 minutes). In addition, heating to 56°C effectively decreased the ability of rFVIII to block antibody binding compared to unheated rFVIII. CONCLUSION: The optimal temperature for PHT in the FVIII NBA is 56°C. Higher temperatures may lead to loss of inhibitory antibodies.
Authors: V S Blanchette; N S Key; L R Ljung; M J Manco-Johnson; H M van den Berg; A Srivastava Journal: J Thromb Haemost Date: 2014-09-03 Impact factor: 5.824
Authors: B Verbruggen; I Novakova; H Wessels; J Boezeman; M van den Berg; E Mauser-Bunschoten Journal: Thromb Haemost Date: 1995-02 Impact factor: 5.249
Authors: Shawn F J Whelan; Christoph J Hofbauer; Frank M Horling; Peter Allacher; Martin J Wolfsegger; Johannes Oldenburg; Christoph Male; Jerzy Windyga; Andreas Tiede; Hans Peter Schwarz; Friedrich Scheiflinger; Birgit M Reipert Journal: Blood Date: 2012-12-12 Impact factor: 22.113
Authors: Silmara Aparecida de Lima Montalvão; Alini Camargo Tucunduva; Andrea Luísa de Almeida Sambo; Erich Vinicius De Paula; Samuel de Souza Medina; Margareth Castro Ozelo Journal: Thromb Res Date: 2015-08-28 Impact factor: 3.944
Authors: Reed W Kamyszek; Matthew W Foster; Brooke A Evans; Keaton Stoner; Jessica Poisson; Amudan J Srinivasan; J Will Thompson; M Arthur Moseley; Micah J Mooberry; Ian J Welsby Journal: Blood Transfus Date: 2020-08-06 Impact factor: 3.443
Authors: Amanda B Payne; Dorothy Ellingsen; Jennifer Driggers; Christopher J Bean; Connie H Miller Journal: Haemophilia Date: 2019-12-06 Impact factor: 4.287
Authors: Andreas Tiede; Peter Collins; Paul Knoebl; Jerome Teitel; Craig Kessler; Midori Shima; Giovanni Di Minno; Roseline d'Oiron; Peter Salaj; Victor Jiménez-Yuste; Angela Huth-Kühne; Paul Giangrande Journal: Haematologica Date: 2020-05-07 Impact factor: 9.941
Authors: Robert Klamroth; Clemens Feistritzer; Ute Friedrich; Steven R Lentz; Kirsten Reichwald; Marek Zak; Pratima Chowdary Journal: J Thromb Haemost Date: 2019-11-15 Impact factor: 5.824
Authors: Laura A Schieve; Vanessa R Byams; Brandi Dupervil; Meredith A Oakley; Connie H Miller; J Michael Soucie; Karon Abe; Christopher J Bean; W Craig Hooper Journal: MMWR Surveill Summ Date: 2020-09-04